Abstract
Following an acute myocardial infarction (AMI), early coronary artery reperfusion remains the most effective means of limiting the eventual infarct size. The resultant left ventricular systolic function is a critical determinant of the patient’s clinical outcome. Despite current myocardial reperfusion strategies and ancillary antithrombotic and antiplatelet therapies, the morbidity and mortality of an AMI remain significant, with the number of patients developing cardiac failure increasing, necessitating the development of novel strategies for cardioprotection which can be applied at the time of myocardial reperfusion to reduce myocardial infarct size. In this regard, the Reperfusion Injury Salvage Kinase (RISK) Pathway, the term given to a group of pro-survival protein kinases (including Akt and Erk1/2), which confer powerful cardioprotection, when activated specifically at the time of myocardial reperfusion, provides an amenable pharmacological target for cardioprotection. Preclinical studies have demonstrated that an increasing number of agents including insulin, erythropoietin, adipocytokines, adenosine, volatile anesthetics natriuretic peptides and ‘statins’, when administered specifically at the time of myocardial reperfusion, reduce myocardial infarct size through the activation of the RISK pathway. This recruits various survival pathways that include the inhibition of mitochondrial permeability transition pore opening. Interestingly, the RISK pathway is also recruited by the cardioprotective phenomena of ischemic preconditioning (IPC) and postconditioning (IPost), enabling the use of pharmacological agents which target the RISK pathway, to be used at the time of myocardial reperfusion, as pharmacological mimetics of IPC and IPost. This article reviews the origins and evolution of the RISK pathway, as part of a potential common cardioprotective pathway, which can be activated by an ever-expanding list of agents administered at the time of myocardial reperfusion, as well as by IPC and IPost. Preliminary clinical studies have demonstrated myocardial protection with several of these pharmacological activators of the RISK pathway in AMI patients undergoing PCI. Through the use of appropriately designed clinical trials, guided by the wealth of existing preclinical data, the administration of pharmacological agents which are known to activate the RISK pathway, when applied as adjuvant therapy to current myocardial reperfusion strategies for patients presenting with an AMI, should lead to improved clinical outcomes in this patient group.
Similar content being viewed by others
References
Yellon DM, Baxter GF (1999) Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245–249
Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61:448–460
Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95:230–232
Hausenloy DJ, Tsang A, Mocanu M, Yellon DM (2005) Ischemic Preconditioning Protects by Activating Pro-Survival Kinases at Reperfusion. Am J Physiol Heart Circ Physiol 288:H971–H976
Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136
Yellon DM, Alkhulaifi AM, Pugsley WB (1993) Preconditioning the human myocardium. Lancet 342:276–277
Heusch G (2001) Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 103:2876–2878
Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM (2005) Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288:H971–H976
Solenkova NV, Solodushko V, Cohen MV, Downey JM (2006) Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 290:H441–H449
Lecour S, Suleman N, Deuchar GA et al (2005) Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112:3911–3918
Zhao ZQ, Corvera JS, Halkos ME et al (2003) Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285:H579–H588
Vinten-Johansen J, Yellon DM, Opie LH (2005) Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 112:2085–2088
Yellon DM, Opie LH (2006) Postconditioning for protection of the infarcting heart. Lancet 367:456–458
Laskey WK (2005) Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 65:361–367
Staat P, Rioufol G, Piot C et al (2005) Postconditioning the human heart. Circulation 112:2143–2148
Ma X, Zhang X, Li C, Luo M (2006) Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 19:367–375
Yang X-C, Liu Y, Wang L-F, Cui L, Ge Y-G, Wang H-S, Li W-M, Xu Li, Ni Z-H, Liu H-S, Zhang L, Wang T, Jia H-M, Vinten-Johansen J., Zhao Z-Q (2006) Permanent reduction in myocardial infarct size by postconditioning in patients after primary coronary angioplasty. Circulation 114:II-812
Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247:127–138
Armstrong SC (2004) Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61:427–436
Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240–253
Inagaki K, Churchill E, Mochly-Rosen D (2006) Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res 70:222–230
Michel MC, Li Y, Heusch G (2001) Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 363:245–266
Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621–1628
Freude B, Masters TN, Robicsek F et al (2000) Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 32:197–208
Zhao ZQ, Morris CD, Budde JM et al (2003) Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile dysfunction during reperfusion. Cardiovasc Res 59:132–142
Mockridge JW, Marber MS, Heads RJ (2000) Activation of Akt during simulated ischemia/reperfusion in cardiac myocytes. Biochem Biophys Res Commun 270:947–952
Yamashita K, Kajstura J, Discher DJ et al (2001) Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 88:609–614
Omura T, Yoshiyama M, Shimada T et al (1999) Activation of mitogen-activated protein kinases in in vivo ischemia/reperfused myocardium in rats. J Mol Cell Cardiol 31:1269–1279
Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ et al (1996) Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79:162–173
Matsui T, Li L, Wu JC et al (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896–22901
Miao W, Luo Z, Kitsis RN, Walsh K (2000) Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol 32:2397–2402
Yue TL, Wang C, Gu JL et al (2000) Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86:692–699
Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM (2001) Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 38:930–939
Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM (2000) Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32:757–764
Jonassen AK, Sack MN, Mjos OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191–1198
Gao F, Gao E, Yue TL et al (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497–1502
Otani H, Yamamura T, Nakao Y et al (2000) Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J Cardiovasc Pharmacol 35:275–281
Brar BK, Stephanou A, Pennica D, Latchman DS (2001) CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 16:93–96
Brar BK, Stephanou A, Liao Z et al (2001) Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 51:265–274
Liao Z, Brar BK, Cai Q et al (2002) Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 53:902–910
Jiang ZS, Padua RR, Ju H et al (2002) Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 282:H1071–H1080
Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 19:1323–1325
Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397–493
Ueda K, Takano H, Hasegawa H et al (2006) Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26:e108–e113
Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM (2006) Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149:5–13
Brar BK, Stephanou A, Knight R, Latchman DS (2002) Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34:483–492
Chanalaris A, Lawrence KM, Stephanou A et al (2003) Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 35:1295–1305
Brar BK, Jonassen AK, Stephanou A et al (2000) Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275:8508–8514
Schulman D, Latchman DS, Yellon DM (2002) Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283:H1481–H1488
Valentim L, Laurence KM, Townsend PA et al (2006) Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol 40:846–852
Yang XM, Krieg T, Cui L, Downey JM, Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36:411–421
Kis A, Baxter GF, Yellon DM (2003) Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther 17:415–425
Park SS, Zhao H, Jang Y, Mueller RA, Xu Z (2006) N6-(3-iodobenzyl)-adenosine-5’-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J Pharmacol Exp Ther 318:124–131
Bell RM, Yellon DM (2003) Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35:185–193
Gross ER, Hsu AK, Gross GJ (2004) Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94:960–966
Hamid SA, Baxter GF (2005) Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol 100:387–396
Bose AK, Mocanu MM, Carr RD, Yellon DM (2005) Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9–11
Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion Injury. Diabetes 54:146–151
Yang XM, Philipp S, Downey JM, Cohen MV (2006) Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101:311–318
Tissier R, Waintraub X, Couvreur N et al (2007) Pharmacological postconditioning with the phytoestrogen genistein. J Mol Cell Cardiol 42:79–87
Zhang SJ, Yang XM, Liu GS, Cohen MV, Pemberton K, Downey JM (2003) CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J Cardiovasc Pharmacol 42:764–771
Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC (2005) Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102:102–109
Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M (2005) Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103:987–995
Pagel PS, Krolikowski JG, Neff DA et al (2006) Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth Analg 102:1348–1354
Feng J, Fischer G, Lucchinetti E et al (2006) Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: role of protein kinase B/Akt signaling. Anesthesiology 104:1004–1014
Weihrauch D, Krolikowski JG, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS (2005) Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesth Analg 101:942–9, table
Krolikowski JG, Weihrauch D, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS (2006) Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Can J Anaesth 53:174–182
Wang C, Neff DA, Krolikowski JG et al (2006) The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic postconditioning in rabbits. Anesth Analg 102:1355–1360
Bell RM, Yellon DM (2003) Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41:508–515
Efthymiou CA, Mocanu MM, Yellon DM (2005) Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45:247–252
Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M (2006) PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res 69:178–185
Manintveld OC, Te Lintel HM, van den Bos EJ et al (2006) Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 292:H1551–H1560
Yang XM, Philipp S, Downey JM, Cohen MV (2005) Postconditioning’s protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100:57–63
Zhu M, Feng J, Lucchinetti E et al (2006) Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 72:152–162
Peng LY, Ma H, He JG et al (2006) [Ischemic postconditioning attenuates ischemia/reperfusion injury in isolated hypertrophied rat heart]. Zhonghua Xin Xue Guan Bing Za Zhi 34:685–689
Zhao, Z-Q, Wang, N-P, Mykytenko, J., Reeves, J, Deneve, J, Jiang, R, Zatta, AJ, Guyton, RA, Vinten-Johansen, J (2006) Postconditioning attenuates cardiac muscle cell apoptosis via translocation of survival kinases and opening of KATP channels in mitochondria. Circulation 114:II-261
Fujita M, Asanuma H, Hirata A et al (2007) Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 292:H2004–H2008
Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K (2005) ‘Postconditioning’ via Stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK 1/2. Am J Physiol Heart Circ Physiol 289:H1618–H1626
Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44:1103–1110
Sun HY, Wang NP, Halkos M et al (2006) Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 11:1583–1593
Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV (2006) Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 70:308–314
Penna C, Rastaldo R, Mancardi D et al (2006) Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 101:180–189
Fantinelli JC, Mosca SM (2007) Comparative effects of ischemic pre and postconditioning on ischemia-reperfusion injury in spontaneously hypertensive rats (SHR). Mol Cell Biochem 296:45–51
Zatta AJ, Kin H, Lee G et al (2006) Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 70:315–324
Suleman N, Opie L, Lecour S (2006) Ischemic postconditioning confers cardioprotection via phosporylation of STAT-3. J Mol Cell Cardiol 40:155
Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M (2005) Postconditioning inhibits mitochondrial permeability transition. Circulation 111:194–197
Burley DS, Baxter GF (2005) Post-conditioning is dependent on pkg activation in early reperfusion. J Mol Cell Cardiol 38:28
da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M (2004) Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology 100:59–69
Fryer RM, Pratt PF, Hsu AK, Gross GJ (2001) Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther 296:642–649
Fryer RM, Patel HH, Hsu AK, Gross GJ (2001) Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am J Physiol Heart Circ Physiol 281:H1184–H1192
Sanada S, Asanuma H, Minamino T et al (2004) Optimal windows of statin use for immediate infarct limitation: 5’-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110:2143–2149
Wynne AM, Mocanu MM, Yellon DM (2005) Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. J Cardiovasc Pharmacol 46:817–822
Bell RM, Clark JE, Hearse DJ, Shattock MJ (2007) Reperfusion kinase phosphorylation is essential but not sufficient in the mediation of pharmacological preconditioning: characterisation in the bi-phasic profile of early and late protection. Cardiovasc Res 73:153–163
Ping P, Murphy E (2000) Role of p38 mitogen-activated protein kinases in preconditioning: a detrimental factor or a protective kinase? Circ Res 86:921–922
Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: United at reperfusion. Pharmacol Therapeutics (in press)
Kin H, Zhao ZQ, Sun HY et al (2004) Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 62:74–85
Griffiths EJ, Halestrap AP (1995) Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307( Pt 1):93–98
Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P (2001) Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276:2571–2575
Kim JS, Jin Y, Lemasters JJ (2006) Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 290:H2024–H2034
Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341(Pt 2):233–249
Hausenloy DJ, Yellon DM (2003) The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35:339–341
Hausenloy DJ, Duchen MR, Yellon DM (2003) Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60:617–625
Lefer AM, Tsao P, Aoki N, Palladino MA Jr (1990) Mediation of cardioprotection by transforming growth factor-beta. Science 249:61–64
Kulik G, Klippel A, Weber MJ (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595–1606
Parrizas M, Saltiel AR, LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272:154–161
Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660–667
Hong F, Kwon SJ, Jhun BS et al (2001) Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci 68:1095–1105
Chao W, Matsui T, Novikov MS et al (2003) Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J Gene Med 5:277–286
Wang L, Ma W, Markovich R, Chen JW, Wang PH (1998) Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 83:516–522
Yamamura T, Otani H, Nakao Y, Hattori R, Osako M, Imamura H (2001) IGF-I differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart. Am J Physiol Heart Circ Physiol 280:H1191–H1200
Pennica D, King KL, Shaw KJ et al (1995) Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92:1142–1146
Sheng Z, Pennica D, Wood WI, Chien KR (1996) Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 122:419–428
Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR (1997) Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy J Biol Chem 272:5783–5791
Buehler A, Martire A, Strohm C et al (2002) Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res 55:768–777
Heusch G (2006) Obesity–a risk factor or a RISK factor for myocardial infarction? Br J Pharmacol 149:1–3
Harada M, Qin Y, Takano H et al (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11:305–311
Kitamura K, Kangawa K, Kawamoto M et al (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553–560
Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J (2003) Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 285:H1506–H1514
Yin H, Chao L, Chao J (2004) Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling. Hypertension 43:109–116
Okumura H, Nagaya N, Itoh T et al (2004) Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109:242–248
Deacon CF (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181–2189
D’Souza SP, Yellon DM, Martin C et al (2003) B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 284:H1592–H1600
Sangawa K, Nakanishi K, Ishino K, Inoue M, Kawada M, Sano S (2004) Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 77:233–237
Patten RD, Pourati I, Aronovitz MJ et al (2004) 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95:692–699
Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC (2004) Adjunctive 17beta-estradiol administration reduces infarct size by altered expression of canine myocardial connexin43 protein. Cardiovasc Res 63:109–117
Stefano GB, Prevot V, Beauvillain JC et al (2000) Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 101:1594–1597
Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541
Piriou V, Chiari P, Gateau-Roesch O et al (2004) Desflurane-induced preconditioning alters calcium-induced mitochondrial permeability transition. Anesthesiology 100:581–588
Raphael J, Abedat S, Rivo J et al (2006) Volatile anesthetic preconditioning attenuates myocardial apoptosis in rabbits after regional ischemia and reperfusion via Akt signaling and modulation of Bcl-2 family proteins. J Pharmacol Exp Ther 318:186–194
Schlack W, Preckel B, Stunneck D, Thamer V (1998) Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart. Br J Anaesth 81:913–919
Preckel B, Schlack W, Comfere T, Obal D, Barthel H, Thamer V (1998) Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 81:905–912
Tessier-Vetzel D, Tissier R, Waintraub X, Ghaleh B, Berdeaux A (2006) Isoflurane inhaled at the onset of reperfusion potentiates the cardioprotective effect of ischemic postconditioning through a NO-dependent mechanism. J Cardiovasc Pharmacol 47:487–492
Venkatapuram S, Wang C, Krolikowski JG et al (2006) Inhibition of apoptotic protein p53 lowers the threshold of isoflurane-induced cardioprotection during early reperfusion in rabbits. Anesth Analg 103:1400–1405
Di Napoli P, Antonio TA, Grilli A et al (2001) Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 51:283–293
Kureishi Y, Luo Z, Shiojima I et al (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004–1010
Schwartz LM, Lagranha CJ (2006) Ischemic postconditioning during reperfusion activates Akt and ERK without protecting against lethal myocardial ischemia-reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 290:H1011–H1018
Heusch G (2004) Postconditioning: old wine in a new bottle? J Am Coll Cardiol 44:1111–1112
Kin H, Zatta AJ, Lofye MT et al (2005) Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67:124–133
Kin H, Zatta AJ, Jiang R, Reeves JG, Mykytenko J, Sorescu GP, Zhao Z-Q, Wang NP, Guyton RA, Vinten-Johansen J (2005) Activation of opioid receptors mediates the infarct size reduction by Postconditioning. J Mol Cell Cardiol 38:827
Marber MS, Latchman DS, Walker JM, Yellon DM (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88:1264–1272
Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ (2001) p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98:9666–9670
Juhaszova M, Zorov DB, Kim SH et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549
Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006) Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:414–419
Costa AD, Garlid KD, West IC et al (2005) Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97:329–336
Andrukhiv A, Costa AD, West IC, Garlid KD (2006) Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol 291:H2067–H2074
Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD (2006) The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 281:20801–20808
Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD (2006) Mitochondrial PKC{epsilon} and Mitochondrial ATP-Sensitive K+ Channel Copurify and Coreconstitute to Form a Functioning Signaling Module in Proteoliposomes. Circ Res 99:878–883
Kim JS, Ohshima S, Pediaditakis P, Lemasters JJ (2004) Nitric oxide: a signaling molecule against mitochondrial permeability transition- and pH-dependent cell death after reperfusion. Free Radic Biol Med 37:1943–1950
Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20:7779–7786
Zuurbier CJ, Eerbeek O, Meijer AJ (2005) Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am J Physiol Heart Circ Physiol 289:H496–H499
Pastorino JG, Hoek JB, Shulga N (2005) Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65:10545–10554
Abdallah Y, Gkatzoflia A, Gligorievski D et al (2006) Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage. Cardiovasc Res 70:346–353
Dosenko VE, Nagibin VS, Tumanovskaya LV, Zagoriy VY, Moibenko AA, Vaage J (2006) Proteasomal proteolysis in anoxia-reoxygenation, preconditioning and postconditioning of isolated cardiomyocytes. Pathophysiology 13:119–125
Hahn HS, Yussman MG, Toyokawa T et al (2002) Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition. Circ Res 91:741–748
Inagaki K, Hahn HS, Dorn GW, Mochly-Rosen D (2003) Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation 108:869–875
Noma K, Oyama N, Liao JK (2006) Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290:C661–C668
Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98:322–334
Bao W, Hu E, Tao L et al (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548–558
Wolfrum S, Dendorfer A, Rikitake Y et al (2004) Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24:1842–1847
Hamid S, Bower HS, Baxter GF (2007) Rho-kinase plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol Jan 12; [Epub ahead of print]
Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M (2004) Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 68:95–100
Schwartz GG, Olsson AG, Ezekowitz MD et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285:1711–1718
Cannon CP, Braunwald E, McCabe CH et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504
Mahaffey KW, Puma JA, Barbagelata NA et al (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711–1720
Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45:1775–1780
Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965
Ehrenreich H, Hasselblatt M, Dembowski C et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505
Lipsic E, van der MP, Voors AA et al (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20:135–141
Lee TM, Su SF, Chou TF, Tsai CH (2002) Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty. J Am Coll Cardiol 39:871–877
Shimokawa H, Hiramori K, Iinuma H et al (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40:751–761
Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E (2005) Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238:31–39
Kishi T, Hirooka Y, Masumoto A et al (2005) Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111:2741–2747
Chyrchel M, Rakowski T, Rzeszutko L et al (2006) Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol 64:1357–1362
Marzilli M, Orsini E, Marraccini P, Testa R (2000) Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101:2154–2159
Quintana M, Hjemdahl P, Sollevi A et al (2003) Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 59:1–9
Mehta SR, Yusuf S, Diaz R et al (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293:437–446
Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS (2000) Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 14:615–623
Apstein CS, Opie LH (2005) A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 26:956–959
Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P (1999) Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 100:II340–II344
Van Der Linden PJ, Daper A, Trenchant A, De Hert SG (2003) Cardioprotective effects of volatile anesthetics in cardiac surgery. Anesthesiology 99:516–517
Symons JA, Myles PS (2006) Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 97:127–136
Takano H, Hasegawa H, Kuwabara Y et al (2006) Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol
Kang HJ, Kim HS, Zhang SY et al (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363:751–756
Hill JM, Syed MA, Arai AE et al (2005) Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46:1643–1648
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hausenloy, D.J., Yellon, D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12, 217–234 (2007). https://doi.org/10.1007/s10741-007-9026-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-007-9026-1